Analyst Ratings For NASDAQ:EDIT – Editas Medicine (NASDAQ:EDIT)
Today, Chardan Capital lowered its price target on NASDAQ:EDIT – Editas Medicine (NASDAQ:EDIT) to per share.
Some recent analyst ratings include
- 3/14/2018-Morgan Stanley Reiterated Rating of Equal Weight ➝ Equal Weight.
- 2/16/2018-Cann Reiterated Rating of Hold.
- 2/13/2018-CLSA initiated coverage with a Underperform ➝ Underperform rating.
- 1/23/2018-SunTrust Banks Upgrade from a “Hold ➝ Buy” rating to a “” rating.
Recent Insider Trading Activity For NASDAQ:EDIT – Editas Medicine (NASDAQ:EDIT)
NASDAQ:EDIT – Editas Medicine (NASDAQ:EDIT) has insider ownership of 19.40% and institutional ownership of 62.98%.
- On 5/1/2018 Katrine Bosley, Insider, sold 8,333 with an average share price of $31.95 per share and the total transaction amounting to $266,239.35.
- On 4/2/2018 Katrine Bosley, Insider, sold 8,333 with an average share price of $32.16 per share and the total transaction amounting to $267,989.28.
- On 3/20/2018 Andrew A F Hack, CFO, sold 40,000 with an average share price of $38.06 per share and the total transaction amounting to $1,522,400.00.
- On 3/16/2018 Andrew A F Hack, CFO, sold 6,000 with an average share price of $39.43 per share and the total transaction amounting to $236,580.00.
- On 3/9/2018 Katrine Bosley, Insider, sold 9,134 with an average share price of $45.00 per share and the total transaction amounting to $411,030.00.
- On 3/1/2018 Katrine Bosley, Insider, sold 8,333 with an average share price of $35.72 per share and the total transaction amounting to $297,654.76.
- On 2/16/2018 Andrew A F Hack, CFO, sold 18,000 with an average share price of $34.21 per share and the total transaction amounting to $615,780.00.
Recent Trading Activity for NASDAQ:EDIT – Editas Medicine (NASDAQ:EDIT)
Shares of NASDAQ:EDIT – Editas Medicine closed the previous trading session at 35.70 down -0.30 0.83% with 122023 shares trading hands.